Array Biopharma Sees Positive Study Results From COLUMBUS Phase 2, But Commercialization May Prove Daunting
May 10, 2017 at 13:12 PM EDT
Following Array Biopharma Inc (NASDAQ: ARRY) reporting positive top line results from part 2 of a late-stage study of its combo ...